Les Ancizes (FR)
{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~22 mi. (Clermont-Ferrand, France, +226 more cities)
facility
Centre Jean Perrin ( Site 0434)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~22 mi. (Clermont-Ferrand, France, +207 more cities)
facility
Centre Jean Perrin ( Site 0909)
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~22 mi. (Clermont-Ferrand, France, +159 more cities)
facility
Centre Jean Perrin ( Site 0460)
condition
Superficial Bladder Urothelial Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~22 mi. (Clermont-Ferrand, France, +137 more cities)
facility
CHU Estaing ( Site 0360)
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
city
~22 mi. (Clermont-Ferrand, France, +70 more cities)
facility
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 0510)
condition
Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~27 mi. (Pessade, France, +140 more cities)
facility
CHU Bordeaux Haut-Leveque ( Site 0185)
condition
Hepatocellular Carcinoma
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
city
~27 mi. (Pessade, France, +105 more cities)
facility
CHU Bordeaux Haut-Leveque ( Site 0457)
condition
Colorectal Adenocarcinoma
drug
bevacizumab, +1 more drug
drug type
targeted therapy
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~27 mi. (Pessade, France, +201 more cities)
facility
CHU Bordeaux - Hopital Haut Lévêque /ID# 220989
condition
Myelodysplastic Syndromes
drug
azacitidine, +1 more drug
drug type
chemotherapy
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
city
~27 mi. (Pessade, France, +127 more cities)
facility
CHU Bordeaux - Hopital Haut Lévêque /ID# 214055
condition
Acute Myeloid Leukemia
drug
azacitidine, +2 more drugs
drug type
chemotherapy